Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 12 · inside the Ichimoku cloud · RSI 52 · MACD above its signal
None of the 29 investors followed here reported a position in BBRRF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BBRRF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.3 | -4.8 | 11.1 | -14.6 | 8.3 | -3.6 | 18.5 | 4.1 | -24.2 | 19.0 | +3.5% | ||
| 2025 | -14.5 | 0.5 | 6.5 | 16.0 | -1.9 | -2.9 | 0.0 | 52.0 | -27.6 | 3.8 | -10.7 | 12.7 | +16.2% |
| 2024 | 29.7 | -11.7 | -0.9 | -33.5 | 43.3 | -11.1 | -22.8 | 15.3 | 26.5 | -19.5 | -16.7 | -1.0 | −28.3% |
| 2023 | 9.8 | -5.5 | 24.8 | -19.9 | -44.4 | 32.2 | 3.7 | 33.3 | -4.5 | -23.6 | -42.9 | 72.5 | −24.2% |
| 2022 | -12.7 | -26.2 | -8.1 | -3.1 | 9.2 | -9.1 | 0.9 | 12.1 | -8.7 | -31.5 | 4.4 | -22.5 | −67.4% |
| 2021 | 22.3 | 53.4 | -6.9 | -26.3 | -19.0 | 18.7 | -23.5 | 6.4 | -16.3 | -6.2 | -7.6 | -4.4 | −30.1% |
| 2020 | 24.1 | -41.2 | -34.3 | -12.8 | 69.1 | -27.7 | -17.9 | -0.5 | 5.8 | -26.5 | 39.5 | 84.3 | −16.6% |
| 2019 | 58.8 | -1.6 | -40.1 | -15.6 | -26.3 | -12.1 | -34.6 | -9.2 | -26.9 | 26.2 | −72.0% |
No insider transactions reported for BBRRF.
No analyst coverage for this instrument.
Blueberries Medical Corp., a consumer science company, engages in the commercialization of medicinal cannabis and related products in Colombia. The company produces and distributes psychoactive and non-psychoactive cannabis derivatives. Blueberries Medical Corp. is based in Vancouver, Canada.